Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
Urologe A ; 56(6): 734-745, 2017 Jun.
Article in German | MEDLINE | ID: mdl-28424831

ABSTRACT

Urinay tract infection (UTI) as one of the most frequent bacterial infections in humans is of utmost relevance. Because of the rising prevalence of antimicrobial resistance, urinalysis should always include urine culture and a resistogram in order to avoid an unspecific selection and overuse of antibiotics. Prevention of recurrent UTI must first of all rule out predisposing uropathogenic conditions. Nowadays, a great variety of drugs, behavioral, and supportive treatment options can effectively minimize UTI recurrence. The growing importance of vaccines (immunotherapy), probiotics (lactobacilli), and standardized herbal preparations meets the need of reducing antibiotic use and the development of antimicrobial resistance. Around 80% of all nosocomial UTIs (nUTIs) are associated with indwelling urinary catheters. It is estimated that up to 70% of all nUTIs occurring in Germany may be avoided by using appropriate preventative measures. Therefore, profound knowledge about the basics of catheter-associated nUTIs and the correct management of urinary catheters are of utmost individual and socioeconomic importance.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Vaccines/therapeutic use , Catheter-Related Infections/prevention & control , Cross Infection/prevention & control , Probiotics/therapeutic use , Urinary Catheters/adverse effects , Urinary Tract Infections/prevention & control , Catheter-Related Infections/etiology , Cross Infection/diagnosis , Cross Infection/etiology , Evidence-Based Medicine , Humans , Recurrence , Secondary Prevention , Treatment Outcome , Urinary Tract Infections/etiology
2.
Aktuelle Urol ; 47(3): 220-8, 2016 05.
Article in German | MEDLINE | ID: mdl-27271450

ABSTRACT

With a share of 22.4%, nosocomial urinary tract infections (nUTIs) are among the most frequent infections acquired in hospitals, along with surgical site infections (24.7%), pneumonia (21.5%), clostridium difficile infections (6.6%) and primary sepsis (6%) 1. 80% of all nUTIs are associated with indwelling urinary catheters, with 12-16% of all hospitalised patients and up to 81.8% of all intensive care patients receiving an indwelling urinary catheter during their hospital stay 2 3. Therefore, profound knowledge about the basics of catheter-associated nUTIs and the correct management of urinary catheters are of utmost individual and socio-economic importance 4 5. It is estimated that up to 70% of all nUTIs occurring in Germany may be avoided by using appropriate preventative measures 6 7.In 2012, the authors Conway and Larson compared 8 recommendations in English language for the prevention of UTIs and noticed that they have been largely consistent over a period of 30 years 8. Special issues have rarely been addressed in valid studies, and study results are rather heterogeneous. For example, the 2008 SHEA (Society of Hospital Epidemiologists of America) guideline contains only 3 recommendations and 4 prohibitions which are based on more than one randomised controlled clinical study 9 10 11.The confirmed recommendations on the prevention of UTIs are consistent in the following aspects 12 13 14 15 16 17: · Every insertion of a urinary catheter must be based on a well-founded medical indication.. · Well-founded medical indications include acute urinary retention, interventions lasting several hours with a high fluid turnover, surgery involving the urinary tract, the necessity to record fluid turnover especially in critically ill patients, comfort for the dying, facilitating wound healing in the external genitals in the presence of urinary incontinence. Examples of unnecessary use of urinary catheters include prescriptions based on urinary incontinence alone and prolongation of use, e. g. after surgical procedures or after intensive care monitoring/recording has been completed.. · The insertion technique as well as catheter care and the detection of catheter-associated complications must be trained continuously.. · Catheterisation must be performed under sterile precautions.. · Only sterile and closed urinary drainage systems may be used.. · Catheters must be removed as early as possible..


Subject(s)
Bacterial Infections/prevention & control , Catheter-Related Infections/prevention & control , Urinary Catheters/microbiology , Urinary Tract Infections/prevention & control , Bacterial Infections/transmission , Catheter-Related Infections/transmission , Catheters, Indwelling/microbiology , Humans , Urinary Tract Infections/transmission
3.
Urologe A ; 53(10): 1458-67, 2014 Oct.
Article in German | MEDLINE | ID: mdl-25292308

ABSTRACT

Nosocomial infections (NI) may be a serious and mostly avoidable consequence of medical procedures and often cause a significant aggravation of the patients underlying disease. Following surgical site infections, urinary tract infections (UTI) represent the second most common fraction of NIs (22.4%) in Germany and contribute to approximately 155,000 nosocomial UTIs (nUTI) every year.Prevention of NI is of utmost individual as well as socioeconomic importance especially regarding the continuing worldwide increase in antibiotic resistance. National legislature has responded to this challenge by amending the German Law on the Prevention and Control of Infectious Diseases (IfSG) and other measures. Their practical importance for various clinical settings in urology is outlined in this overview.The correct use of urinary catheters has the greatest impact for prevention and control as nUTIs are associated with urinary catheters in most of the cases (80%). The recently updated guidelines of the Commission for Hospital Hygiene and Infection Prevention of the Robert Koch Institute (KRINKO) and the Association of the Scientific Medical Societies in Germany (AWMF) provide detailed recommendations in an evidence-based and practice-oriented manner as summarized in this article.


Subject(s)
Catheter-Related Infections/epidemiology , Catheter-Related Infections/prevention & control , Cross Infection/epidemiology , Cross Infection/prevention & control , Practice Guidelines as Topic , Urinary Tract Infections/epidemiology , Urinary Tract Infections/prevention & control , Germany/epidemiology , Guideline Adherence , Humans , Prevalence , Risk Factors , Urology/standards
4.
Urologe A ; 53(10): 1468-75, 2014 Oct.
Article in German | MEDLINE | ID: mdl-25292309

ABSTRACT

BACKGROUND: Recurrent urinary tract infections (rUTI), defined as ≥ 3 UTIs per year, mostly affect young and postmenopausal women. Treatable predisposing factors are rare. METHODS: General recommendations to reduce rUTIs lower the recurrence rate by up to approximately two thirds. Continuous long-term prophylaxis (LP) with low dose antibiotics or single postcoital doses can reduce the recurrence rate of rUTIs to as low as 5%. According to the European Association of Urology guidelines nitrofurantoin, trimethoprim and co-trimoxazole are the first-line drugs and cephalosporins or fluoroquinolones should be restricted to specific indications. Oral and parenteral immunotherapy were found to be effective in several controlled studies for prevention of rUTIs and can be combined with acute antibiotic therapy. CONCLUSIONS: Vaginal prophylaxis with estriol has proven its positive effect without serious gynecological side effects and there is also increasing evidence that cranberries prevent rUTIs but the exact mode of this therapy remains to be defined. There are also other promising modalities, such as phytotherapeutics, mannose, urine acidification, influencing bacterial intestinal and vaginal flora and the general immune response by e.g. acupuncture and inpatient rehabilitation, the therapeutic value of which still has to be proven.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Bacterial Infections/prevention & control , Practice Guidelines as Topic , Risk Reduction Behavior , Urinary Tract Infections/prevention & control , Urology/standards , Bacterial Infections/drug therapy , Europe , Female , Humans , Recurrence , Urinary Tract Infections/drug therapy
5.
Minerva Urol Nefrol ; 65(1): 9-20, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23538307

ABSTRACT

Urinary tract infections (UTI) are among the most frequent bacterial infections in the community and health care setting. Mostly young and, to some extent, postmenopausal women are affected by recurrent UTI (rUTI) defined as ≥3 UTI/year or ≥2 UTI/half year. In contrast, rUTI is rare in healthy men. On the other hand, rUTI are frequently found in female and male patients with complicating urological factors, e.g. urinary catheters, infection stones. Remediable predisposing factors in uncomplicated rUTI in women are rare. In complicated rUTI the success depends mainly on the possibility to eliminate or at leastimprove the complicating risk factors. Continuous antibiotic prophylaxis or postcoital prophylaxis, if there is close correlation with sexual intercourse, are most effective to prevent rUTI. Nitrofurantoin, trimethoprim (or cotrimoxazole), and fosfomycin trometamol are available as first-line drugs. Oral cephalosporins and quinolones should be restricted to specific indications. Antibiotic prophylaxis reduces the number of uropathogens in the gut and/or vaginal flora and reduces bacterial "fitness". Given the correct indication, the recurrence rate of rUTI can be reduced by about 90%. Due to possible adverse events and the concern of selecting resistant pathogens, according to the guidelines of the European Association of Urology antimicrobial prophylaxis should be considered only after counselling, behavioural modification and non-antimicrobial measures have been attempted. In postmenopausal patients vaginal substitution of oestriol should be started first. Oral or parenteral immunoprophylaxis is another option in patients with rUTI. Other possibilities with varying scientific evidence are prophylaxis with cranberry products, specific plant combinations or probiotics. The prophylaxis of catheter-associated UTI should employ strategies which result in a reduction of frequency and duration of catheter drainage of the urinary tract. The currently available catheter materials have only little influence on reducing catheter-associated rUTI.


Subject(s)
Urinary Tract Infections/prevention & control , Adjuvants, Immunologic/therapeutic use , Anti-Infective Agents/therapeutic use , Antibiotic Prophylaxis , Catheter-Related Infections/etiology , Catheter-Related Infections/prevention & control , Coitus , Diuretics/therapeutic use , Estrogen Replacement Therapy , Female , Humans , Hygiene , Intestines/microbiology , Male , Phytotherapy , Probiotics/therapeutic use , Risk Factors , Secondary Prevention , Urinary Catheterization/adverse effects , Urinary Tract Infections/epidemiology , Urinary Tract Infections/etiology , Vagina/microbiology
6.
Urologe A ; 51(4): 500, 502-6, 2012 Apr.
Article in German | MEDLINE | ID: mdl-22476801

ABSTRACT

In contrast to ureterosigmoidostomy no reliable clinical data exist for tumor risk in different forms of urinary diversion using isolated intestinal segments.In 44 German urological departments, operation frequencies, indications, patient age, and operation dates of the different forms of urinary diversion, operated between 1970 and 2007, could be registered. The secondary tumors up to 2009 were registered as well and related to the numbers of the different forms of urinary diversions resulting in tumor prevalences.In 17,758 urinary diversions 32 secondary tumors occurred. The tumor risk in ureterosigmoidostomy (22-fold) and cystoplasty (13-fold) is significantly higher than in other continent forms of urinary diversion such as neobladders or pouches (p<0.0001). The difference between ureterosigmoidostomy and cystoplasty is not significant, nor is the difference between ileocecal pouches (0.14%) and ileal neobladders (0.05%) (p=0.46). The tumor risk in ileocecal (1.26%) and colonic neobladders (1.43%) is significantly higher (p=0.0001) than in ileal neobladders (0.5%). Of the 16 tumors that occurred following ureterosigmoidostomy, 16 (94%) developed directly at the ureterocolonic borderline in contrast to only 50% following urinary diversions via isolated intestinal segments.From postoperative year 5 regular endoscopic controls of ureterosigmoidostomies, cystoplasties, and orthotopic (ileo-)colonic neobladders are necessary. In ileocecal pouches, regular endoscopy is necessary at least in the presence of symptoms or should be performed routinely at greater intervals. Following neobladders or conduits, only urethroscopies for urethral recurrence are necessary.


Subject(s)
Anastomosis, Surgical/statistics & numerical data , Postoperative Complications/epidemiology , Urinary Diversion/statistics & numerical data , Urogenital Neoplasms/epidemiology , Adult , Age Distribution , Aged , Aged, 80 and over , Female , Germany/epidemiology , Humans , Male , Middle Aged , Prevalence , Risk Assessment , Risk Factors , Young Adult
7.
Urologe A ; 50(10): 1248, 1250-2, 1254-6, 2011 Oct.
Article in German | MEDLINE | ID: mdl-21927878

ABSTRACT

Urinary tract infections (UTI) are among the most frequent bacterial infections in the community and health care setting. Mostly young and, to some extent, postmenopausal women are affected by recurrent UTI (rUTI) defined as ≥3 UTI/year. On the other hand rUTI are frequently found in patients with complicating urological factors, e.g. urinary catheters. Modifiable predisposing factors in uncomplicated rUTI in women are rare. Continuous antibiotic prophylaxis or postcoital prophylaxis, if there is close correlation with sexual intercourse, are most effective to prevent rUTI. Nitrofurantoin, trimethoprim (or cotrimoxazole), and fosfomycin trometamol are available as first-line drugs. Oral cephalosporins and quinolones should be restricted to specific indications. Antibiotic prophylaxis reduces the number of uropathogens in the gut and/or vaginal flora and reduces bacterial"fitness". Given the correct indication, the recurrence rate of rUTI can be reduced by about 90%. In postmenopausal patients vaginal substitution of oestriol should be started first. Oral or parenteral immunoprophylaxis is another option in patients with rUTI. Other possibilities with varying scientific evidence are prophylaxis with cranberries or probiotics. The prophylaxis of catheter-associated UTI or asymptomatic bacteriuria should employ strategies which result in a reduction of frequency and duration of catheter drainage of the urinary tract. The currently available catheter materials have only little influence on reducing catheter-associated rUTI.


Subject(s)
Anti-Infective Agents, Urinary/therapeutic use , Primary Prevention , Secondary Prevention , Urinary Tract Infections/prevention & control , Antibiotic Prophylaxis , Bacterial Vaccines/therapeutic use , Dose-Response Relationship, Drug , Drug Administration Schedule , Estradiol/therapeutic use , Estrogen Replacement Therapy , Female , Humans , Male , Phytotherapy/methods , Probiotics/therapeutic use , Urinary Tract Infections/etiology , Vaccinium macrocarpon
8.
Urologe A ; 45(4): 421-7, 2006 Apr.
Article in German | MEDLINE | ID: mdl-16532350

ABSTRACT

The basis for the diagnostic work-up of recurrent cystitis is formed by taking a precise medical history against the background of knowledge of the pathogenesis of urinary tract infections. The anamnesis should also focus on factors that influence the natural flora (sexual intercourse, hygiene) but additionally include preceding antibiotic treatment and diseases that affect the immune status (diabetes mellitus). Urinalysis is the principal examination among the laboratory diagnostic procedures. The diagnosis is promptly confirmed by immediate analysis of a clean catch midstream urine sample using a counting chamber or a test strip. As a matter of principle, microbiological diagnosis always ensues. Extended diagnostic work-up (urological staging) is aimed at detecting functional and anatomic abnormalities. While these factors only play a subordinate role during the premenopausal phase, they gain in importance during the postmenopausal phase. A key role is also attributed to local estrogen deficiency.


Subject(s)
Bacteriuria/diagnosis , Cystitis/diagnosis , Anti-Infective Agents, Urinary/therapeutic use , Bacteriuria/etiology , Bacteriuria/microbiology , Colony Count, Microbial , Cystitis/etiology , Cystitis/microbiology , Humans , Microbial Sensitivity Tests , Microbiological Techniques , Reagent Strips , Recurrence , Risk Factors , Specimen Handling
10.
Aktuelle Urol ; 36(4): 329-36, 2005 Aug.
Article in German | MEDLINE | ID: mdl-16110406

ABSTRACT

Urinary tract obstruction is a common clinical problem. The obstruction of the urinary flow may be acute or chronic, partial or complete, unilateral or bilateral, and may occur at any site of the urinary tract. The major causes of urinary tract obstruction vary with the age of the patient. Anatomic abnormalities, e. g. ureteropelvic junction obstruction, account for the majority of cases in children. In comparison, calculi are most common in young adults, while prostatic hyperplasia or carcinoma, retroperitoneal or pelvic neoplasms, and calculi are the primary causes in older patients. Urinary tract obstruction results in different pathophysiological changes causing various symptoms. In addition to the aetiology, pathophysiology and clinical presentation of obstructive uropathy in adults, modern diagnostic and therapeutic options are presented in this review.


Subject(s)
Hydronephrosis , Kidney Calculi , Prostatic Hyperplasia , Ureteral Calculi , Ureteral Obstruction , Ureterocele , Urination Disorders/etiology , Adult , Age Factors , Cystoscopy , Female , Humans , Hydronephrosis/diagnosis , Hydronephrosis/surgery , Kidney Calculi/diagnosis , Kidney Calculi/therapy , Kidney Neoplasms/complications , Laparoscopy , Magnetic Resonance Imaging , Male , Pregnancy , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/diagnosis , Prostatic Hyperplasia/surgery , Tomography, X-Ray Computed , Ultrasonography , Ureteral Calculi/diagnostic imaging , Ureteral Calculi/therapy , Ureteral Obstruction/diagnosis , Ureteral Obstruction/diagnostic imaging , Ureteral Obstruction/surgery , Ureterocele/diagnosis , Ureterocele/diagnostic imaging , Urethra/abnormalities , Urethra/diagnostic imaging , Urethral Neoplasms/complications , Urethral Neoplasms/diagnostic imaging , Urinary Bladder Neoplasms/complications , Urinary Bladder Neoplasms/diagnostic imaging , Urinary Catheterization , Urography
11.
Aktuelle Urol ; 36(4): 342-8, 2005 Aug.
Article in German | MEDLINE | ID: mdl-16110408

ABSTRACT

Hormone-refractory prostate cancer is diagnosed with increasing incidence and has become a growing challenge for urologists. The improved understanding of the tumor biological mechanisms of the hormone-refractory state has led to innovative therapeutic developments in the field of hormonal and cytotoxic therapies. Recently, two large randomized Phase III trials with docetaxel-based chemotherapy were able to show prolonged survival and a positive influence on pain and quality of life, establishing a new standard of care for these patients. Moreover, bisphosphonates seem to have positive influence on selected patients. In the growing field of molecular targeted therapy, first trials with compounds, such as tyrosine kinase inhibitors, anti-sense oligonucleotides, angiogenesis inhibitors and endothelin receptor antagonists, show promising results in the treatment of patients with hormone-refractory prostate cancer.


Subject(s)
Prostatic Neoplasms/drug therapy , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Diphosphonates/administration & dosage , Diphosphonates/therapeutic use , Docetaxel , Drug Resistance, Neoplasm , Endothelin Receptor Antagonists , Humans , Male , Meta-Analysis as Topic , Mitoxantrone/administration & dosage , Mitoxantrone/therapeutic use , Mutation , Oligonucleotides, Antisense/therapeutic use , Patient Selection , Prostatic Neoplasms/genetics , Prostatic Neoplasms/mortality , Prostatic Neoplasms/physiopathology , Protein-Tyrosine Kinases/antagonists & inhibitors , Quality of Life , Randomized Controlled Trials as Topic , Receptors, Androgen/genetics , Taxoids/administration & dosage , Taxoids/therapeutic use , Time Factors , Trastuzumab
12.
Urologe A ; 43(2): 185-9, 2004 Feb.
Article in German | MEDLINE | ID: mdl-14991121

ABSTRACT

Gross hematuria without pain is a classical symptom of malignancy in the urinary tract. Despite the presence of other symptoms such as a history of heavy smoking or radiologic evidence of tumor growth, it may still be caused by a benign lesion. This is demonstrated by the case of a 38 year old man with a fibroepithelioma of the left ureter. While discussing the differential diagnostic and treatment procedures it is shown that even in the era of modern non-invasive imaging techniques there is still an important place for retrograde ureteropyelography in the evaluation of the upper urinary tract.


Subject(s)
Hematuria/diagnosis , Hematuria/etiology , Neoplasms, Fibroepithelial/complications , Neoplasms, Fibroepithelial/diagnosis , Ureteral Neoplasms/complications , Ureteral Neoplasms/diagnosis , Adult , Diagnosis, Differential , Humans , Male , Pain/diagnosis , Pain/etiology , Urography , Urologic Neoplasms/diagnosis
13.
Urologe A ; 42(8): 1060-9, 2003 Aug.
Article in German | MEDLINE | ID: mdl-14513230

ABSTRACT

In the last few years, progress in the field of catheter drainage of the urinary tract was limited to the introduction of some new devices, materials, and catheter coatings as well as specific points of technique [37]. At the same time a substantial number of evidence-based guidelines for the use of urinary catheters have been developed by various institutions [9, 13, 15, 17, 23, 28, 39], aiming at a reduction of catheter-associated nosocomial urinary tract infections. Based on these guidelines, this article provides a detailed overview of the current state of the art of catheter drainage of the urinary tract, focussing on practical aspects and hygiene. Urinary tract infections (UTI) still account for 30-40% of all nosocomial infections nowadays, while 90% of these nosocomial UTIs are associated with urinary catheters! The prevention of catheter-associated nosocomial UTIs, therefore, is an individual as well as infectiological and socioeconomic issue of utmost importance requiring cost-effective surveillance strategies and modern individualized concepts for the catheter drainage of the urinary tract in a multidisciplinary approach. Continuous training and education must ensure the above-mentioned medical standards since nurses, outpatient health care networks, and patients themselves increasingly assume the management of catheter drainage of the urinary tract. Because of their unique and specific expertise, urologists have to take responsibility and must play a key role in these projects.


Subject(s)
Catheters, Indwelling , Urinary Catheterization/instrumentation , Catheters, Indwelling/adverse effects , Cross Infection/etiology , Cross Infection/prevention & control , Equipment Failure Analysis , Humans , Patient Care Team , Patient Education as Topic , Prosthesis Design , Risk Factors , Urinary Tract Infections/etiology , Urinary Tract Infections/prevention & control
14.
Urologe A ; 42(8): 1074-86, 2003 Aug.
Article in German | MEDLINE | ID: mdl-14513232

ABSTRACT

Of 405 patients with stage IV transitional cell carcinoma from an international multicenter phase III trial, 70 were randomized in Germany to receive either gemcitabine/cisplatin or standard MVAC systemic chemotherapy for locally advanced or metastatic urothelial cancer. Overall survival as the primary endpoint of the study was similar in both arms (median survival GC 15.4 months vs MVAC 16.1 months), as were tumor-specific survival and time to progressive disease. In the intent-to-treat analysis, the 5-year overall survival rate was 10% for patients randomized to GC and 18% randomized to MVAC. Tumor overall response rates (GC 54%, MVAC 53%) were similar. The toxic death rate was 0% in the GC arm and 3% (one patient) in the MVAC arm. Significantly more GC than MVAC patients experienced grade 3/4 anemia (GC 52%, MVAC 20%) with significantly more red blood cell transfusions in the GC arm.Significantly more GC than MVAC patients had grade 3/4 thrombocytopenia (GC 54%, MVAC 17%) without grade 3/4 hemorrhage or hematuria in either arm. More MVAC patients experienced grade 3/4 neutropenia (GC 56%, MVAC 61%, p=1.000), neutropenic or leukopenic fever (GC 0%, MVAC 10%, p=0.237), mucositis (GC 0%, MVAC 7%, p=0.495), and alopecia (GC 6%, MVAC 36%, p=0.004). GC represents a reasonable alternative for the palliative treatment of patients with locally advanced and metastatic transitional cell carcinoma. Sustained long-term survival was only found for patients with locally advanced cancer, lymphatic metastases, or solitary distant metastasis but not for visceral metastatic disease.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Transitional Cell/drug therapy , Cisplatin/administration & dosage , Deoxycytidine/analogs & derivatives , Deoxycytidine/administration & dosage , Doxorubicin/administration & dosage , Methotrexate/administration & dosage , Palliative Care , Urologic Neoplasms/drug therapy , Vinblastine/administration & dosage , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma, Transitional Cell/mortality , Carcinoma, Transitional Cell/pathology , Cisplatin/adverse effects , Deoxycytidine/adverse effects , Disease Progression , Doxorubicin/adverse effects , Female , Follow-Up Studies , Humans , Lymphatic Metastasis/pathology , Male , Methotrexate/adverse effects , Middle Aged , Neoplasm Staging , Prospective Studies , Survival Rate , Urologic Neoplasms/mortality , Urologic Neoplasms/pathology , Vinblastine/adverse effects , Gemcitabine
15.
Urologe A ; 42(1): 104-12, 2003 Jan.
Article in German | MEDLINE | ID: mdl-12577160

ABSTRACT

Today, the classical bacteria that cause venereal diseases, e.g. gonorrhea, syphilis, chancroid and inguinal granuloma, only account for a small proportion of all known sexually transmitted diseases (STDs). Other bacteria and viruses as well as yeasts, protozoa and epizoa must also be regarded as causative organisms of STD. Taken together, all sexually transmitted infections comprise more than 30 relevant STD pathogens. However, not all pathogens that can be sexually transmitted manifest diseases in the genitals and not all infections of the genitals are exclusively sexually transmitted. Concise information and tables summarising the diagnostic and therapeutic management of STDs in the field of urology allow a synoptic overview, and are in agreement with the recent international guidelines of other specialist areas. Special considerations (i.e. HIV infection, pregnancy, infants, allergy) and recommended regimens are presented.


Subject(s)
Genital Diseases, Male/diagnosis , Sexually Transmitted Diseases/diagnosis , Disease Notification/legislation & jurisprudence , Female , Genital Diseases, Male/therapy , Germany , Humans , Infant, Newborn , Male , Pregnancy , Sexually Transmitted Diseases/therapy , Societies, Medical
16.
J Biol Chem ; 276(36): 33741-6, 2001 Sep 07.
Article in English | MEDLINE | ID: mdl-11447227

ABSTRACT

The kidney, and more specifically the proximal tubule, is the main site of elimination of cationic endogenous metabolites and xenobiotics. Although numerous studies exist on renal organic cation transport of rat and rabbit, no information is available from humans. Therefore, we examined organic cation transport and its regulation across the basolateral membrane of isolated human proximal tubules. mRNA for the cation transporters hOCT1 and hOCT2 as well as hOCTN1 and hOCTN2 was detected in these tubules. Organic cation transport across the basolateral membrane of isolated collapsed proximal tubules was recorded with the fluorescent dye 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP(+)). Depolarization of the cells by rising extracellular K(+) concentration to 145 mm reduced ASP(+) uptake by 20 +/- 5% (n = 15), indicating its electrogeneity. The substrates of organic cation transport tetraethylammonium (K(i) = 63 microm) and cimetidine (K(i) = 11 microm) as well as the inhibitor quinine (K(i) = 2.9 microm) reduced ASP(+) uptake concentration dependently. Maximal inhibition reached with these substances was approximately 60%. Stimulation of protein kinase C with 1,2-dioctanoyl-sn-glycerol (DOG, 1 microm) or ATP (100 microm) inhibited ASP(+) uptake by 30 +/- 3 (n = 16) and 38 +/- 13% (n = 6), respectively. The effect of DOG could be reduced with calphostin C (0.1 microm, n = 7). Activation of adenylate cyclase by forskolin (1 microm) decreased ASP(+) uptake by 29 +/- 3% (n = 10). hANP (10 nm) or 8-bromo-cGMP (100 microm) also decreased ASP(+) uptake by 17 +/- 3 (n = 9) or 32 +/- 5% (n = 10), respectively. We show for the first time that organic cation transport across the basolateral membrane of isolated human proximal tubules, most likely mediated via hOCT2, is electrogenic and regulated by protein kinase C, the cAMP- and the cGMP-dependent protein kinases.


Subject(s)
Cations , Fluorescent Dyes/pharmacology , Kidney Tubules/metabolism , Pyridinium Compounds/pharmacology , Biological Transport , Cell Membrane/metabolism , Cloning, Molecular , Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclic GMP/analogs & derivatives , Cyclic GMP/metabolism , Diglycerides/metabolism , Dose-Response Relationship, Drug , HeLa Cells , Humans , Kinetics , Potassium/pharmacology , Protein Kinase C/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Spectrometry, Fluorescence
17.
Urology ; 56(2): 315-6, 2000 Aug 01.
Article in English | MEDLINE | ID: mdl-10925102

ABSTRACT

We describe a newly developed suprapubic catheterization set with a defined sigmoidal, geometrically and functionally tripartite tip and grooved trocar shaft. The device was designed to enhance the handling and safety features of the current commercially available sets to promote the broader application of suprapubic catheterization.


Subject(s)
Cystostomy/instrumentation , Surgical Instruments , Urinary Catheterization/instrumentation , Cross Infection/prevention & control , Equipment Design , Humans , Urinary Tract Infections/prevention & control
18.
BJU Int ; 85(3): 362-71, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10671897

ABSTRACT

OBJECTIVE: To determine the functional potential and antigenicity of the homologous bladder acellular matrix graft (BAMG) in a dog model. MATERIALS AND METHODS: Seven mongrel dogs underwent partial cystectomy (20-50%) and grafting with an equal-sized BAMG; two control animals underwent partial cystectomy (40%) only. The dogs were killed after 30 (one), 120 (one) and 210 days (five dogs). Blood samples were obtained before and at 1, 2, 4, 7, 14, 30, 90 and 210 days after surgery. The dogs underwent cystography, intravenous pyelography and ultrasonography before and after surgery, and on the day they were killed, with cystoscopy carried out just before death. The grafted tissue was assessed using routine and immunohistochemical techniques. RESULTS: All the dogs survived surgery; a complete blood cell count, chemical panel and white blood cell count showed no significant difference between the experimental and control animals. Cystography, cystoscopy and ultrasonography revealed no pathological changes in the upper urinary tract. After 7 months, the mean bladder capacity in the augmented dogs was significantly higher (P = 0.035) than in the controls (264 vs 172 mL). Histological evaluation showed an invasion of all bladder wall components during the first month; at 7 months, the morphological examination showed essentially complete regeneration. CONCLUSION: In this dog model, the potential of the BAMG as a bladder augmentation graft was confirmed, having minimal antigenicity with maximal acceptance. The reconstructed bladder matched the morphological and functional properties of the normal bladder.


Subject(s)
Cystectomy/methods , Urinary Bladder/surgery , Animals , Dogs , Graft Survival/physiology , Male , Surgical Flaps/pathology , Urinary Bladder/anatomy & histology
19.
Urologe A ; 39(6): 530-4, 2000 Nov.
Article in German | MEDLINE | ID: mdl-11138271

ABSTRACT

Interstitial cystitis (IC) represents a rare and complex inflammatory bladder condition in which diagnostics can be challenging. Strict NIH criteria for its diagnosis were designed for research purposes. Their routine application would miss large proportions of IC patients. When IC is suspected, history and physical exam are followed by an evaluation of long-term voiding diaries. Large voided volumes (functional capacity > 250 cc) or longer micturition intervals (> 2 h.), absence of nocturia or symptom-free periods reduce the likelihood of IC. Further exclusion diagnostics include urine tests (infection), cytology (in-situ carcinoma), ultrasound (calculi, bulks, anomalies) and urodynamics in selected cases. Bladder capacity measurements under sedoanalgesia are of limited value, since functional low-volume bladders can be mechanically extendable. Cystoscopy under general anesthesia represents the diagnostic standard procedure for IC during which 90% of IC-patients present with characteristic mucosal glomerulations after bladder distension. Biopsies are recommended for exclusion of malignancy. Potassium-leak testing plays no relevant role in routine diagnostics due to its poor sensitivity. Similarly, complex determinations of novel IC markers (histamine, tryptase, cytokines, growth factors, substance P, nitric oxide) are of no relevance in clinical settings and should be restricted to research projects.


Subject(s)
Cystitis, Interstitial/diagnosis , Biopsy , Cystoscopy , Diagnosis, Differential , Humans , Urinary Bladder/pathology , Urine/chemistry , Urine/cytology , Urodynamics/physiology
20.
Urologe A ; 39(6): 535-8, 2000 Nov.
Article in German | MEDLINE | ID: mdl-11138272

ABSTRACT

Up to now there is no specific treatment targeting the ultimate cause of interstitial cystitis (IC), since its pathogenesis and etiology are still unknown. Most studies focussing on oral medication have not been randomized, double-blinded or placebo-controlled. Numerous case reports and intent-to-treat trials are lacking a systematic approach and do not meet evidence-based medicine criteria. Consequently there is as yet no standard oral therapy available for the treatment of IC. However, only a few oral substances have shown a potential to improve symptoms such as frequency and pain. The best results were obtained from monotherapeutic use of pentosanpolysulfate, amitriptylin and hydroxycin. The true benefit of these substances alone should be compared to analgesics and anticholinergics in the course of controlled clinical trials.


Subject(s)
Cystitis, Interstitial/drug therapy , Administration, Oral , Amitriptyline/administration & dosage , Analgesics/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Cystitis, Interstitial/etiology , Humans , Hydroxyzine/administration & dosage , Pentosan Sulfuric Polyester/administration & dosage , Steroids , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...